Lnc2Cancer

Experimentally Supported Human LncRNA and Cancer Associations Database

LncRNA centric

Cancer centric

Advanced search

Drug resistant

Circulating

Prognosis

Detail


   LncRNA Name CCAT1
   Synonyms CCAT1, CARLo-5, onco-lncRNA-40
   Region GRCh38_8:127207382-127219268    Sequence
   Ensembl ENSG00000247844
   RefSeq NR_108049
   Circulating
   Drug-resisitant
   Prognostic
   MiRNA
   Variant
   TF
   Methylation
   Cancer Name multiple myeloma
   ICD-0-3 C42.1  M9732/3
   Methods qPCR, Luciferase reporter assay, Western blot
   Sample cell lines (RPMI-8226, U266, MM.1S, KM3 and H929)
   Expression Pattern up-regulated
   Function Description

the relative expression levels of CCAT1 were significantly upregulated in MM tissues and cell lines compared with healthy donors and normal plasma cells (nPCs). High expression of CCAT1 was correlated shorter overall survival of MM patients. CCAT1 knockdown significantly inhibited cell proliferation, induced cell cycle arrest at G0/G1 phase and promoted cell apoptosis in vitro, and suppressed tumor growth in vivo. MiR-181a-5p was a direct target of CCAT1, and repression of miR-181a-5p could rescue the inhibition of CCAT1 knockdown on MM progression. In addition,CCAT1 positively regulated HOXA1 expression through sponging miR-181a-5p in MM cells. lncRNA CCAT1 exerted an oncogenic role in MM by acting as a ceRNA of miR-181a-5p. These results suggest that CCAT1 may serve as a novel diagnostic marker and therapeutic target for MM.

   Pubmed ID 29228867
   Year 2017
   Title Long non-coding RNA CCAT1 promotes multiple myeloma progression by acting as a molecular sponge of miR-181a-5p to modulate HOXA1 expression.
   External Links
   Links for  CCAT1 GenBank       HGNC       lncrnadb       Noncode
   Links for  multiple myeloma Omim       Cosmic

CopyRight © College of Bioinformatics Science and Technology, Harbin Medical University, China.